Literature DB >> 22711610

Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.

Pascale This1, Anne de la Rochefordière, Alexia Savignoni, Marie Christine Falcou, Anne Tardivon, Fabienne Thibault, Séverine Alran, Virgine Fourchotte, Alfred Fitoussi, Benoit Couturaud, Sylvie Dolbeault, Remy J Salmon, Brigitte Sigal-Zafrani, Bernard Asselain, Dominique Stoppa-Lyonnet.   

Abstract

Description of the various modalities of breast and ovarian cancer risk management, patient choices and their outcome in a single-center cohort of 158 unaffected women carrying a BRCA1 or BRCA2 germline mutation. Between 1998 and 2009, 158 unaffected women carrying a BRCA1 or BRCA2 gene mutation were prospectively followed. The following variables were studied: general and gynecological characteristics, data concerning any prophylactic procedures, and data concerning the outcome of these patients. Median age at inclusion was 37 years and median follow-up was 54 months. Among the 156 women who received systematic information about prophylactic mastectomy, 5.3 % decided to undergo surgery within 36 months after disclosure of genetic results. Prophylactic salpingo-oophorectomy was performed in 68 women. Among women in whom follow-up started between the ages of 40 and 50 years, prophylactic salpingo-oophorectomy was performed, within 24 months after start of follow-up, in 83.7 and 52 % of women with BRCA1 and BRCA2 mutations, respectively. Twenty four women developed breast cancer. Ovarian cancer was detected during prophylactic salpingo-oophorectomy in two women (2.9 %). In this cohort of French women carrying BRCA1/2 mutations, prophylactic mastectomy was a rarely used option. However, good compliance with prophylactic salpingo-oophorectomy was observed. This study confirms the high breast cancer risk in these women.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711610     DOI: 10.1007/s10689-012-9539-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  42 in total

1.  Variation in prophylactic surgery decisions.

Authors:  C Julian-Reynier; F Eisinger; G Evans; W Foulkes; H Sobol
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

2.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.

Authors:  Ellen Warner; Kimberley Hill; Petrina Causer; Donald Plewes; Roberta Jong; Martin Yaffe; William D Foulkes; Parviz Ghadirian; Henry Lynch; Fergus Couch; John Wong; Frances Wright; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Authors:  Amy Finch; Mario Beiner; Jan Lubinski; Henry T Lynch; Pal Moller; Barry Rosen; Joan Murphy; Parviz Ghadirian; Eitan Friedman; William D Foulkes; Charmaine Kim-Sing; Teresa Wagner; Nadine Tung; Fergus Couch; Dominique Stoppa-Lyonnet; Peter Ainsworth; Mary Daly; Babara Pasini; Ruth Gershoni-Baruch; Charis Eng; Olufunmilayo I Olopade; Jane McLennan; Beth Karlan; Jeffrey Weitzel; Ping Sun; Steven A Narod
Journal:  JAMA       Date:  2006-07-12       Impact factor: 56.272

4.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

5.  Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.

Authors:  K A Metcalfe; A Poll; A O'Connor; S Gershman; S Armel; A Finch; R Demsky; B Rosen; S A Narod
Journal:  Clin Genet       Date:  2007-09       Impact factor: 4.438

Review 6.  Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.

Authors:  M J Bermejo-Pérez; S Márquez-Calderón; A Llanos-Méndez
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

7.  Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Authors:  Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

8.  Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study.

Authors:  Yvonne Brandberg; Kerstin Sandelin; Staffan Erikson; Göran Jurell; Annelie Liljegren; Annika Lindblom; Ann Lindén; Anna von Wachenfeldt; Marie Wickman; Brita Arver
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

9.  Significant contribution of germline BRCA2 rearrangements in male breast cancer families.

Authors:  Isabelle Tournier; Brigitte Bressac-de Paillerets; Hagay Sobol; Dominique Stoppa-Lyonnet; Rosette Lidereau; Michel Barrois; Sylvie Mazoyer; Florence Coulet; Agnès Hardouin; Agnès Chompret; Alain Lortholary; Pierre Chappuis; Violaine Bourdon; Valérie Bonadona; Christine Maugard; Brigitte Gilbert; Catherine Nogues; Thierry Frébourg; Mario Tosi
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

10.  Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers.

Authors:  Angela R Bradbury; Comfort N Ibe; James J Dignam; Shelly A Cummings; Marion Verp; Melody A White; Grazia Artioli; Laura Dudlicek; Olufunmilayo I Olopade
Journal:  Genet Med       Date:  2008-03       Impact factor: 8.822

View more
  1 in total

1.  International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.

Authors:  Kelly Metcalfe; Andrea Eisen; Leigha Senter; Susan Armel; Louise Bordeleau; Wendy S Meschino; Tuya Pal; Henry T Lynch; Nadine M Tung; Ava Kwong; Peter Ainsworth; Beth Karlan; Pal Moller; Charis Eng; Jeffrey N Weitzel; Ping Sun; Jan Lubinski; Steven A Narod
Journal:  Br J Cancer       Date:  2019-04-11       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.